Inventor
Martin P. Maguire
Inventor
Woburn, MA, US
Overview
Patents· 34 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds29%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%
A61KPreparations for medical, dental or toiletry purposes22%
C07CAcyclic or carbocyclic compounds21%
C07HSugars2%
PatentTitleYear
10,117,848Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof201810,010,522Short acting phenylalkylamine calcium channel blockers and uses thereof201810,010,523Short acting phenylalkylamine calcium channel blockers and uses thereof201810,010,524Short acting phenylalkylamine calcium channel blockers and uses thereof20189,737,503'Short acting phenylalkylamine calcium channel blockers and uses thereof'20179,463,179'Short acting phenylalkylamine calcium channel blockers and uses thereof'20169,227,918'Short acting phenylalkylamine calcium channel blockers and uses thereof'20168,501,727'Short acting benzothiazepine calcium channel blockers and uses thereof'20137,550,597'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20097,375,125'Melanocortin-4 receptor binding compounds and methods of use thereof'20086,921,821'Antagonists of melanin concentrating hormone receptor'20056,852,712'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20056,846,815'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20056,821,962'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases'20046,699,873'Melanocortin-4 receptor binding compounds and methods of use thereof'20046,696,434'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20046,645,969'Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase'20036,559,313'Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties'20036,528,526'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20036,524,347'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20036,376,472'Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties'2002RE037650'Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase'20026,180,632'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases'20016,159,978'Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56.sup.lck tyrosine kinases'20006,057,320'Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase'2000RE036256'Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase'19995,795,889'Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase'19985,721,237'Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties'19985,714,493'Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase'19985,710,158'Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase'19985,656,643'Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase'19975,646,153'Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase'19975,556,990'Polyarylcarbamoylaza- and -carbamoylalkanedioic acids'19965,480,883'Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase'1996Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1996–1999Patents assigned to RHONE POULENC RORER PHARMA (9)· patent assignee history
1996–2003Based in Mont Clare, PA, US· patent location history
2000–2001Patents assigned to AVENTIS PHARM PROD INC (3)· patent assignee history
2000–2009Based in Woburn, MA, US· patent location history
2000Based in Louisville, KY, US· patent location history
2002–2009Patents assigned to AVENTIS PHARMA INC (9)· patent assignee history
2003–2004Based in Cambridge, MA, US· patent location history
2005Patents assigned to ABBOTT LAB (1)· patent assignee history
2013–2018Patents assigned to MILESTONE PHARMACEUTICALS INC (8)· patent assignee history
2013–2018Based in Westmount, CA· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| AVENTIS PHARMA INC | 9 | 2002–2009 |
| RHONE POULENC RORER PHARMA | 9 | 1996–1999 |
| MILESTONE PHARMACEUTICALS INC | 8 | 2013–2018 |
| AVENTIS PHARM PROD INC | 3 | 2000–2001 |
| ABBOTT LAB | 1 | 2005 |
Locations
| Location | Patents | Span |
|---|---|---|
| Woburn, Massachusetts, US | 12 | 2000–2009 |
| Mont Clare, Pennsylvania, US | 10 | 1996–2003 |
| Westmount, CA | 8 | 2013–2018 |
| Cambridge, Massachusetts, US | 2 | 2003–2004 |
| Louisville, KY, US | 1 | 2000 |